Propensity score analysis of radical cystectomy versus bladder-sparing trimodal therapy in the setting of a multidisciplinary bladder cancer clinic

Journal of Clinical Oncology

Volumn 35, Issue 20, 2017, Pages 2299-2305

  Kulkarni, Girish S ^a   Hermanns, Thomas ^a   Wei, Yanliang ^a   Bhindi, Bimal ^a   Satkunasivam, Raj ^a   Athanasopoulos, Paul ^a   Bostrom, Peter J ^a   Li, Kathy ^a   Templeton, Arnoud J ^a   Sridhar, Srikala S ^a   Chung, Peter ^a   Bristow, Robert G ^a   Milosevic, Michael ^a   Warde, Padraig ^a   Fleshner, Neil E ^a   Jewett, Michael A S ^a   Bashir, Shaheena ^a   Zlotta, Alexandre R ^a,b   Kuk, Cynthia ^b   Van Der Kwast, Theodorus H ^c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; CISPLATIN; GEMCITABINE; ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; BLADDER SPARING TRIMODAL THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CHARLSON COMORBIDITY INDEX; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; CYSTECTOMY; DISEASE SPECIFIC SURVIVAL; EASTERN COOPERATIVE ONCOLOGY GROUP STATUS; ENDOSCOPIC SURGERY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLOW UP; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MUSCLE INVASIVE BLADDER CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPENSITY SCORE; RADIOSENSITIZATION; RETROSPECTIVE STUDY; TRANSURETHRAL RESECTION; BLADDER; CANCER STAGING; CARCINOMA; COMPARATIVE STUDY; CONSERVATIVE TREATMENT; DISEASE FREE SURVIVAL; MIDDLE AGED; PATHOLOGY; PATIENT CARE; RADIOTHERAPY; SURVIVAL RATE; TUMOR INVASION; URINARY BLADDER NEOPLASMS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA; COMBINED MODALITY THERAPY; CYSTECTOMY; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORGAN SPARING TREATMENTS; PATIENT CARE TEAM; PROPENSITY SCORE; RADIOTHERAPY; RETROSPECTIVE STUDIES; SURVIVAL RATE; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 85027000834     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2016.69.2327     Document Type: Conference Paper

References (32)

1. Kulkarni GS, Urbach DR, Austin PC, et al: Higher surgeon and hospital volume improves longterm survival after radical cystectomy. Cancer 119: 3546-3554, 2013
2. Christodouleas JP, Baumann BC, He J, et al: Optimizing bladder cancer locoregional failure risk stratification after radical cystectomy using SWOG 8710. Cancer 120:1272-1280, 2014
3. Hermans TJ, Fransen van de Putte EE, Horenblas S, et al: Perioperative treatment and radical cystectomy for bladder cancer: A population-based trend analysis of 10,338 patients in the Netherlands. Eur J Cancer 54:18-26, 2016
4. Grossman HB, Natale RB, Tangen CM, et al: Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 349:859-866, 2003
5. Turker P, Bostrom PJ, Wroclawski ML, et al: Upstaging of urothelial cancer at the time of radical cystectomy: Factors associated with upstaging and its effect on outcome. BJU Int 110:804-811, 2012
6. Prades J, Remue E, van Hoof E, et al: Is it worth reorganising cancer services on the basis of multidisciplinary teams (MDTs)? A systematic review of the objectives and organisation of MDTs and their impact on patient outcomes. Health Policy 119: 464-474, 2015
7. Pillay B, Wootten AC, Crowe H, et al: The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treat Rev 42:56-72, 2016
8. De Palma R, Liberati A, Ciccone G, et al: Developing clinical recommendations for breast, colorectal, and lung cancer adjuvant treatments using the GRADE system: A study from the Programma Ricerca e Innovazione Emilia Romagna oncology research group. J Clin Oncol 26:1033-1039, 2008
9. Berho M, Narang R, Van Koughnett JA, et al: Modern multidisciplinary perioperative management of rectal cancer. JAMA Surg 150:260-266, 2015
10. Mak RH, Hunt D, Shipley WU, et al: Long-term outcomes in patients with muscle-invasive bladder cancer after selective bladder-preserving combinedmodality therapy: A pooled analysis of Radiation Therapy Oncology Group protocols 8802, 8903, 9506, 9706, 9906, and 0233. J Clin Oncol 32: 3801-3809, 2014
11. Chung PW, Bristow RG, Milosevic MF, et al: Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol 25: 303-309, 2007
12. Efstathiou JA, Spiegel DY, Shipley WU, et al: Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer: The MGH experience. Eur Urol 61: 705-711, 2012
13. James ND, Hussain SA, Hall E, et al: Radiotherapy with or without chemotherapy in muscleinvasive bladder cancer. N Engl J Med 366: 1477-1488, 2012
14. Gofrit ON, Nof R, Meirovitz A, et al: Radical cystectomy vs. chemoradiation in T2-4aN0M0 bladder cancer: A case-control study. Urol Oncol 33: 19.e1-19.e5, 2015
15. Bostrom PJ, Toren PJ, Xi H, et al: Point-of-care clinical documentation: assessment of a bladder cancer informatics tool (eCancerCareBladder): A randomized controlled study of efficacy, efficiency and user friendliness compared with standard electronic medical records. J Am Med Inform Assoc 18: 835-841, 2011
16. Bhindi B, Yu J, Kuk C, et al: The importance of surgeon characteristics on impacting oncologic outcomes for patients undergoing radical cystectomy. J Urol 192:714-719, 2014
17. Galsky MD, Hahn NM, Rosenberg J, et al: Treatment of patients with metastatic urothelial cancer unfit for cisplatin-based chemotherapy. J Clin Oncol 29:2432-2438, 2011
18. Lamm DL, Blumenstein BA, Crissman JD, et al: Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1, and carcinoma in situ transitional cell carcinoma of the bladder: A randomized Southwest Oncology Group study. J Urol 163:1124-1129, 2000
19. Kassouf W, Kamat AM, Zlotta A, et al: Canadian guidelines for treatment of non-muscle invasive bladder cancer: A focus on intravesical therapy. Can Urol Assoc J 4:168-173, 2010
20. Hall MC, Chang SS, Dalbagni G, et al: Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update. J Urol 178:2314-2330, 2007
21. Babjuk M, Burger M, Zigeuner R, et al: EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2013. Eur Urol 64: 639-653, 2013
22. Heinze G, Ju? ni P: An overview of the objectives of and the approaches to propensity score analyses. Eur Heart J 32:1704-1708, 2011
23. Huddart RA, Hall E, Lewis R, et al: Life and death of spare (selective bladder preservation against radical excision): Reflections on why the spare trial closed. BJU Int 106:753-755, 2010
24. Choudhury A, Swindell R, Logue JP, et al: Phase II study of conformal hypofractionated radiotherapy with concurrent gemcitabine in muscleinvasive bladder cancer. J Clin Oncol 29:733-738, 2011
25. Bostrom PJ, van Rhijn BWG, Fleshner N, et al: Staging and staging errors in bladder cancer. Eur Urol Suppl 9:2-9, 2010
26. Booth CM, Siemens DR, Peng Y, et al: Patterns of referral for perioperative chemotherapy among patientswith muscle-invasive bladder cancer: A population-based study. Urol Oncol 32:1200-1208, 2014
27. Nayan M, Bhindi B, Yu JL, et al: The initiation of a multidisciplinary bladder cancer clinic and the uptake of neoadjuvant chemotherapy: A time-series analysis. Can Urol Assoc J 10:25-30, 2016
28. Gore JL, Litwin MS, Lai J, et al: Use of radical cystectomy for patientswith invasive bladder cancer. J Natl Cancer Inst 102:802-811, 2010
29. Tilki D, Reich O, Karakiewicz PI, et al: Validation of the AJCC TNM substaging of pT2 bladder cancer: Deep muscle invasion is associated with significantly worse outcome. Eur Urol 58:112-117, 2010
30. Gakis G, Schilling D, Renninger M, et al: Comparison of the new American Joint Committee on Cancer substratification in node-negative pT2 urothelial carcinoma of the bladder: Analysis of patient outcomes in a contemporary series. BJU Int 107:919-923, 2011
31. Zehnder P, Studer UE, Skinner EC, et al: Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: A comparative study. J Urol 186: 1261-1268, 2011
32. Sonpavde G, Khan MM, Lerner SP, et al: Disease-free survival at 2 or 3 years correlates with 5-year overall survival of patients undergoing radical cystectomy for muscle invasive bladder cancer. J Urol 185:456-461, 2011